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Background: The nuclear poly(A) binding protein 1 (PABPN1) is a ubiquitously expressed protein that plays critical roles
at multiple steps in post-transcriptional regulation of gene expression. Short expansions of the polyalanine tract in the
N-terminus of PABPN1 lead to oculopharyngeal muscular dystrophy (OPMD), which is an adult onset disease
characterized by eyelid drooping, difficulty in swallowing, and weakness in the proximal limb muscles. Why alanine-
expanded PABPN1 leads to muscle-specific pathology is unknown. Given the general function of PABPN1 in RNA
metabolism, intrinsic characteristics of skeletal muscle may make this tissue susceptible to the effects of mutant PABPN1.
Methods: To begin to understand the muscle specificity of OPMD, we investigated the steady-state levels of PABPN1 in
different tissues of humans and mice. Additionally, we analyzed the levels of PABPN1 during muscle regeneration after
injury in mice. Furthermore, we assessed the dynamics of PABPN1 mRNA decay in skeletal muscle compared to kidney.
Results: Here, we show that the steady-state levels of both PABPN1 mRNA and protein are drastically lower in mouse
and human skeletal muscle, particularly those impacted in OPMD, compared to other tissues. In contrast, PABPN1 levels
are increased during muscle regeneration, suggesting a greater requirement for PABPN1 function during tissue repair.
Further analysis indicates that modulation of PABPN1 expression is likely due to post-transcriptional mechanisms acting
at the level of mRNA stability.
Conclusions: Our results demonstrate that PABPN1 steady-state levels and likely control of expression differ
significantly in skeletal muscle as compared to other tissues, which could have important implications for
understanding the muscle-specific nature of OPMD.
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RNA-binding proteins regulate all steps of RNA biogen-
esis and play a key role in post-transcriptional regulation
of gene expression [1]. Key players among these RNA-
binding proteins are the poly(A)-binding proteins, which
modulate 3′-end formation of mRNA transcripts [2].
The nuclear poly (A)-binding protein 1 (PABPN1) is a
ubiquitously expressed protein in eukaryotes that binds
with high affinity to polyadenosine RNA [2]. PABPN1
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reproduction in any medium, provided the orregulation of gene expression. The best characterized
role of PABPN1 is in mRNA polyadenylation, where
PABPN1 stimulates poly(A) synthesis by direct inter-
action with the nascent mRNA poly(A) tail and the poly
(A) polymerase [3,4]. In a subsequent regulatory step,
PABPN1 decreases poly(A) polymerase elongation activ-
ity following addition of 250 adenine residues, thereby
dictating the length of the poly(A) tail added to mRNA
transcripts [4]. Moreover, PABPN1 is also involved in
regulation of alternative cleavage and polyadenylation by
suppressing weak proximal polyadenylation signals [5],
which can influence both gene expression and the struc-
ture of the protein produced [6]. Finally, PABPN1 has
been implicated in the polyadenylation-dependent path-
way of RNA decay, which targets non-protein codingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Thus, PABPN1 modulates a number of processes that
are critical for controlling gene expression.
In addition to playing a key role in RNA metabolism,
PABPN1 is of significant clinical interest as mutations in
the PABPN1 gene lead to oculopharyngeal muscular dys-
trophy (OPMD) [8]. This disease is caused by a small
GCN trinucleotide expansion in the coding region of
PABPN1, resulting in the expansion of a stretch of 10 ala-
nines to 12 to 17 alanines in the PABPN1 N-terminus.
OPMD is a late onset, autosomal dominant disease char-
acterized primarily by progressive eyelid drooping (ptosis)
and difficulties in swallowing [9]. Additional weakness is
noted in proximal limb, facial and other extraocular
muscles [10-12]. Disease progression is variable between
patients and complications include choking, regurgitation,
aspiration and pneumonia. The pathologic hallmark of the
disease is the presence of nuclear aggregates of PABPN1
in muscle [13,14]. Given the ubiquitous expression and
general function of PABPN1 in RNA metabolism [15],
how mutations of this post-transcriptional regulatory fac-
tor cause a muscle-specific disease is unclear. PABPN1 is
essential for both mRNA biogenesis as well as prolifera-
tion and differentiation of myogenic precursor cells,
suggesting a critical role in muscle regeneration and main-
tenance [16]. Skeletal muscle is highly specialized for con-
traction and has unique characteristics compared to other
tissues, such as being highly regenerative and comprised
of multinucleated post-mitotic cells, which suggests that
intrinsic characteristics of this tissue may make it more
vulnerable to the effects of mutant PABPN1 than other
tissues that are not affected in OPMD.
To begin to understand the muscle specificity of
OPMD, we investigated the steady-state levels of the
PABPN1 protein in different tissues. We find that the
steady-state levels of PABPN1 are drastically lower in
skeletal muscle compared to other tissues. Strikingly,
craniofacial muscles, which are affected in OPMD, show
the lowest levels of PABPN1. We also found that PABPN1
is upregulated during muscle repair after injury. Studies of
mRNA stability indicate that regulation of PABPN1 ex-
pression is likely due to distinct post-transcriptional
mechanisms in different tissues. Taken together, our re-
sults demonstrate that PABPN1 steady-state levels and
likely control of expression differ significantly in skeletal
muscle as compared to other tissues, which could have
important implications for understanding the muscle-
specific nature of OPMD.
Methods
Animals and primary muscle cell culture
Experiments involving animals were performed in ac-
cordance with approved guidelines and ethical approval
from Emory University’s Institutional Animal Care andUse Committee. Adult male C57BL/6 mice between 2 to
6 months of age were used in experiments. To induce
regeneration, gastrocnemius muscles of male mice were
injected with 40 μl of 1.2% BaCl2 [17] and collected 2, 5
and 14 days after injury. Primary myoblasts were derived
from the hindlimb muscles of mice and cultured to >99%
purity as previously described [18]. Cells were maintained
in growth media (GM: Ham’s F10, 20% fetal bovine serum,
5 ng/ml basic fibroblast growth factor (bFGF), 100 U/ml
penicillin G, 100 mg/ml streptomycin) in a humidified 5%
CO2 incubator at 37°C on collagen-coated dishes. For histo-
logic analyses, serial 10 μm sections were collected along
the length of the muscle and stained with hematoxylin and
eosin. Images were obtained using Axiovert 200 M
microscope with a 0.30 NA 10× or 20× Plan-Neofluar
objective (Carl Zeiss MicroImaging, Inc., Oberkochen,
Germany) and camera (QImaging, Surrey, Canada)
with OpenLab 5.5.2 (PerkinElmer, Waltham, MA).
Immunoblot analysis
Tissues were homogenized in radioimmunoprecipitation
assay (RIPA)-2 buffer (50 mM Tris-HCl pH 8.0, 150
mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1%
SDS) with protease inhibitors (Complete Mini Tablets,
Roche, Pleasanton, CA). Equal amounts of total pro-
tein were resolved by SDS-PAGE, transferred to nitro-
cellulose and the desired protein was detected by
immunoblotting with appropriate antibodies and en-
hanced chemiluminescence. PABPN1 levels in human
tissues were analyzed using INSTA-blot (IMGENEX,
San Diego, CA) membranes. The primary antibodies
and concentrations used were as follows: anti-PABPN1
antibody 1:5,000 [16], anti-Histone H3 1:1,000 (Abcam,
Cambridge, MA), anti-heat shock protein 90 (HSP90)
1:1,000 (Santa Cruz Biotechnology, Dallas, TX) and
anti-tubulin 1:5,000 (Sigma-Aldrich, St. Louis, MO). Anti-
mouse or anti-rabbit IgG 1:5,000 (Jackson ImmunoResearch,
West Grove, PA) were used as secondary antibodies.
Northern blot analysis
Total RNA from tissues, primary cell cultures and
fluorescence-activated cell sorting (FACS)-sorted cells
was isolated using TRIzol (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Northern
blotting was performed as described previously by
Ausubel et al. [19]. DNA probes were generated by
polymerase chain reaction (PCR) using custom primers
(PABPN1-F 5′-CCCAGGCAATGCTGGCCCAGTGAT




primers from SA Biosciences, Valencia, CA (peroxisome
proliferator-activated receptor gamma coactivator 1α
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hydrogenase (GAPDH); PPM02946E) or by Ambion,
Austin, TX (QuantumRNA Classic II 18S). PCR products
were labeled with [α-32P]dCTP using a random primer
DNA labeling system (Invitrogen, Carlsbad, CA).FACS
Mononucleated cells were enzymatically isolated from
gastrocnemius muscles 3 days after BaCl2 injury and
fluorescently labeled with antibodies to CD31 and CD45
(PE), Sca-1 (PE-Cy7), and alpha-7-integrin (AlexaFluor
649). Propidium iodide staining was used to gate out
dead cells from the sort. Myoblasts (CD31-/CD45-/Sca-
1-/alpha-7-integrin+/PI-) and non-myogenic cells (CD31+
/CD45+/Sca-1+/alpha-7-integrin-/PI-) were collected using
a FACSAria II (Becton-Dickinson, Franklin Lakes, NJ).
Isolated cells were then processed for RNA extraction.Quantitative reverse transcription (RT)-PCR
cDNA synthesis from 100 ng RNA was performed using
M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA).
mRNA levels were determined by real-time PCR using
the iQ SYBR Green (Bio-Rad, Hercules, CA) and iCycler
iQ Real-Time Detection System and software (Bio-Rad,
Hercules, CA). The relative levels of PABPN1 were de-
termined by the ΔΔCt method and normalized to the
housekeeping gene HPRT1. Primers were from SA
Bioscences, Valencia, CA (PABPN1: PPM25445A, HPRT1:
PPM03559E).mRNA decay
To analyze mRNA stability in vivo, mice were injected
intraperitoneally with actinomycin D (Sigma-Aldrich, St.
Louis, MO) at 2.5 μg/g and quadriceps muscles and kid-
ney were collected 1, 2, 4 and 6 h later. To measure
mRNA stability in primary myoblasts in vitro, 5 μg/ml
actinomycin D was added to the growth medium and
cells were harvested 0.5, 1, 2 and 4 h later. Total RNA
was extracted from tissues or cells and analyzed by north-
ern blot and half-lives were determined by densitometry.Figure 1 Nuclear poly(A) binding protein 1 (PABPN1) levels are
low in all skeletal muscles. Lysates prepared from different (A)
mouse tissues (50 μg of total protein per lane), (B) mouse muscles
(150 μg of total protein per lane) or (C) human tissues (20 μg of
total protein per lane) were immunoblotted with anti-PABPN1
antibody. Histone H3 and heat shock protein 90 (HSP90) were used
as loading controls for mouse samples. Amido black staining was
used as the loading control for human samples. Immunoblots are
representative of at least three independent sets of tissues.5′ and 3′ RACE
In order to determine the 5′ and 3′UTRs of PABPN1
transcripts, we used the 5′ and 3′ rapid amplification
of cDNA ends (RACE) system (Invitrogen, Carlsbad,
CA), respectively. Total RNA from either muscle or
testis was used as a template according to the manu-
facturer’s instructions. PCR products were cloned into
the pCR2.1 vector (TOPO TA cloning, Invitrogen,
Carlsbad, CA) and sequenced by Beckman Coulter
Genomics, Danvers, MA.Statistical analysis
Statistical analysis to determine significance between
two groups was performed using a Student’s t test.
One-way analysis of variance (ANOVA) was used for
comparisons between multiple groups as appropriate.
All statistical analyses were performed using GraphPad
Prism 5.0 for Macintosh (GraphPad Software). Differ-
ences were considered to be statistically significant at
P <0.05.
Results
PABPN1 levels are lower in skeletal muscle compared to
other tissues
A better understanding of the mechanisms that underlie
OPMD pathology can be obtained by analyzing the func-
tion of PABPN1 in skeletal muscle. To begin to identify
muscle-specific properties of PABPN1, we first examined
the expression of PABPN1 across different tissues. Im-
munoblot analysis revealed that PABPN1 steady-state
levels vary significantly among mouse tissues, with skeletal
muscle displaying the lowest levels of PABPN1 (Figure 1A).
The low abundance of PABPN1 in skeletal muscle could
result from skewed misrepresentation of this protein
within the protein pool by the uniquely high levels of
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ery in this tissue. However, relatively similar levels of both
the nuclear protein histone H3 [20] and the cytoplasmic
protein HSP90 [21] were observed between muscle and
other tissues, suggesting that the nuclear protein fraction
is not under-represented in muscle. Furthermore, analysis
of PABPN1 levels among different mouse muscles re-
vealed even lower levels of this protein in the craniofacial
muscles (masseter, tongue and pharynx), some of which
are muscles primarily affected in OPMD patients [12],
compared to other muscles of the body (Figure 1B). Sig-
nificantly lower levels of PABPN1 in muscle as compared
to other tissues were also observed in human samples
(Figure 1C), suggesting that the low levels of this pro-
tein in muscle are not species-specific findings, and
this may have physiologic implications for humans.
To examine whether the expression of PABPN1 is reg-
ulated at the protein or RNA level we performed north-
ern blot analysis (Figure 2). This analysis revealed a
strong correlation between the low levels of PABPN1
protein and the low abundance of PABPN1 transcript in
mouse skeletal muscle (Figure 2B), suggesting that con-
trol of PABPN1 expression occurs at the RNA level, ei-
ther by transcriptional or post-transcriptional means. As
previously reported, PABPN1 has two major mRNA vari-
ants, a 2.1 kb and a 1.4 kb transcript (Figure 2) [22,23].Figure 2 Nuclear poly(A) binding protein 1 (PABPN1) mRNA
levels are low in skeletal muscle. (A) Structure of the 2.1 kb and
1.4 kb PABPN1 transcripts (solid boxes represent coding regions and
open boxes non-coding regions). (B) Total RNA from different
mouse tissues was analyzed by northern blot using a PABPN1 probe.
Two different exposures, short and long, are shown. 18S rRNA was
probed as a loading control. Figure is representative of at least three
independent sets of tissues.The 2.1 kb transcript, which was detected in all tissues
but was present at low levels in muscle (Figure 2B), uti-
lizes a distal polyadenylation site 851 bp downstream of
the stop codon (Figure 2A) [23]. The 1.4 kb represents
the transcript that uses a proximal polyadenylation site
66 bp downstream of the stop codon (Figure 2A) [23].
This 1.4 kb mRNA variant was the predominant tran-
script only in testis, but was also found in other tissues
at much smaller amounts (Figure 2B). Interestingly, the
levels of the 1.4 kb PABPN1 transcript were very high in
testis, which correlates with the very high levels of
PABPN1 protein observed in this tissue (Additional file
1: Figure S1). Furthermore, with the exception of testis,
no significant variation in the ratio between the two
mRNA isoforms was observed in the analyzed tissues.
Northern blotting also revealed a band of approximately
3.6 kb that was observed in all tissues (data not shown).
This transcript was previously reported and suggested to
be either a transcript of a related gene [22] or generated
by a distinct PABPN1 promoter [23]. We performed
both 5′RACE and 3′RACE from kidney, muscle and
testis but failed to identify any novel PABPN1 transcript
other than the 1.4 kb and 2.1 kb mRNAs variants,
suggesting the 3.6 kb band might indeed represent a
transcript from a related gene. Together, our results
from immunoblotting and northern blotting reveal low
steady-state levels of PABPN1 mRNA and protein in
skeletal muscle, which is indicative of either a decrease
in PABPN1 transcription or altered mRNA stability in
this tissue.
PABPN1 levels are increased during muscle regeneration
Adult skeletal muscle is comprised primarily of post-
mitotic myofibers, however, it is a highly regenerative tis-
sue that undergoes extensive repair after injury (Figure 3A)
[24]. In the earliest phases of muscle regeneration, inflam-
matory cells invade the tissue to remove dead tissue.
Subsequently, large numbers of proliferative myoblasts
derived from resident stem cells undergo differenti-
ation and fusion to form new myofibers. Although
PABPN1 levels are very low in adult muscle tissue,
levels were significantly increased during the period of
extensive cellular proliferation, differentiation and fusion
that occurs 2 to 5 days after muscle injury (Figure 3B).
However, 14 days after injury, when muscle architecture
was restored (Figure 3A), PABPN1 levels were again low
(Figure 3B). A similar pattern of upregulation was ob-
served for the cytoplasmic poly(A) binding protein,
PABPC1 [2], during muscle regeneration, however the
levels of the heat shock protein HSP90 remained constant
over the time course. This result indicates that increased
levels of poly(A)-binding proteins during muscle regener-
ation are not unique to PABPN1. To determine whether
the increased levels of PABPN1 observed at 2 to 5 days
Figure 3 Nuclear poly(A) binding protein 1 (PABPN1) levels are increased during muscle regeneration in part due to increased levels in
myoblasts. (A) Representative hematoxylin and eosin stained sections of gastrocnemius muscles at different times after BaCl2 injury are shown.
(B) Lysates were prepared from gastrocnemius muscles at different times after injury and were immunoblotted with anti-PABPN1, PABPC1 or heat
shock protein 90 (HSP90) antibodies (n = 3 per timepoint). (C) Total RNA was obtained from uninjured and injured muscle tissue (three
independent samples) as well as fluorescence-activated cell sorting (FACS)-sorted myoblasts and non-myogenic cells obtained 3 days after
muscle injury (pooled from five mice). PABPN1 mRNA levels were determined using real-time polymerase chain reaction (PCR) and hypoxanthine-
guanine phosphoribosyltransferase (HPRT) mRNA was used as an internal control. Amount of PABPN1 mRNA relative to uninjured muscle is
shown; n = 3. Data are mean ± SD; *P <0.05 vs uninjured muscle.
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cytometry and specific antibodies to isolate myoblasts and
non-myogenic cells (including inflammatory cells) from
mouse muscles 3 days after injury. As we were unable to
perform immunoblots for PABPN1 on the small amount
of cells isolated by flow cytometry, we used quantitative
RT-PCR to examine PABPN1 transcript levels in sorted
cells compared to muscle tissue. Similar to what we ob-
served for PABPN1 protein, PABPN1 transcript levels
were increased approximately fivefold in injured com-
pared to uninjured muscle (Figure 3C). We also found that
PABPN1 mRNA levels were exceptionally high in both
sorted myoblasts (CD31-/CD45-/Sca-1-/alpha-7-integrin+)
and non-myogenic cells (CD31+/CD45+/Sca-1+/alpha-7-in-
tegrin-) compared to uninjured muscle tissue (Figure 3C).
These data suggest that myoblasts significantly contribute
to increased PABPN1 levels in regenerating muscle. We
conclude that PABPN1 levels are not static in muscle but
rather modulated by the physiologic state of the tissue,
suggesting a greater requirement for PABPN1 function dur-
ing tissue repair.
PABPN1 mRNA is unstable in skeletal muscle
The two PABPN1 transcripts schematized in Figure 2A
arise from the usage of two different polyadenylation
sites. The smaller 1.4 kb transcript contains virtually no
3′UTR, whereas the longer 2.1 kb transcript harbors a
3′UTR of 851 bp containing a putative mRNA AU-rich
destabilizing element (ARE) [23]. We hypothesized that the
2.1 kb transcript, which is the most abundant transcript inall tissues but testis and contains a putative ARE, may be
subject to post-transcriptional regulation in different tis-
sues. To assess if this transcript is differently regulated in
muscle, we analyzed PABPN1 mRNA stability in muscle
and kidney after blocking transcription in mice with acti-
nomycin D. We observed that the half-life of the 2.1 kb
PABPN1 transcript was significantly shorter in muscle
(2.3 h) compared to kidney (>6 h) (Figure 4A,E;
Table 1). As a control to demonstrate similar transcrip-
tional inhibition between both tissues, we analyzed the
stability of PGC1α and GAPDH mRNAs, known un-
stable and stable transcripts, respectively [25,26]. As
expected, PGC1α mRNA displayed a short half-life in
both muscle and kidney (1.7 h and 2.6 h) compared to
GAPDH mRNA (>>6 h in both tissues) (Figure 4A,E;
Table 1). These results demonstrate a strong correl-
ation between the high steady-state levels of PABPN1
protein and the stable transcript in kidney, whereas in
skeletal muscle, the low steady-state levels of PABPN1
correlate with the unstable PABPN1 transcript.
As shown earlier (Figure 3C), PABPN1 levels are mod-
ulated during muscle regeneration and myoblasts con-
tribute in part to the increased levels of PABPN1 during
this process. We next investigated if the increase in
PABPN1 levels in myoblasts is accompanied by a corre-
sponding increase in PABPN1 mRNA stability. Similar
to myoblasts directly isolated from injured muscle, we
found that cultured primary mouse myoblasts displayed
higher levels of PABPN1 mRNA compared to uninjured
muscle tissue (Figure 4B). Consistent with this finding,
Figure 4 Nuclear poly(A) binding protein 1 (PABPN1) mRNA is unstable in muscle tissue but stable in cultured myoblasts. (A) Total RNA
was collected at different timepoints after injection of actinomycin D to inhibit transcription and PABPN1 mRNA decay was analyzed by northern
blot. Time courses are shown for samples from muscle and kidney. Peroxisome proliferator-activated receptor gamma coactivator 1α (PGC1α) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a known unstable and stable transcript, respectively, were probed as controls (n = 3 per
timepoint). To visualize PABPN1 signal in muscle samples, the blot was exposed significantly longer than for kidney samples. (B) Total RNA was
obtained from skeletal muscle (SM) and cultured primary mouse myoblasts (Mb) and PABPN1 mRNA levels were determined using real-time
polymerase chain reaction (PCR) and hypoxanthine-guanine phosphoribosyltransferase (HPRT) mRNA was used as an internal control. The amount
of PABPN1 mRNA relative to skeletal muscle (SM) is shown; n = 3 independent samples. Data are mean ± SD; *P <0.05 vs skeletal muscle. (C)
Protein extracts were prepared from SM and Mb and immunoblotted with anti-PABPN1 antibody. HSP90 was used as a loading control. The
immunoblot is representative of at least three independent samples. (D) Total RNA was collected at different timepoints after treatment of
cultured primary mouse myoblasts with actinomycin D and PABPN1 mRNA decay was analyzed by northern blot; c-Myc and GAPDH, known
unstable and stable transcripts in myoblasts, respectively, were probed as controls. Averages of densitometric measurements of northern blot
bands were used to determine mRNA decay. The image is representative of at least three independent samples. (E) The decay profile of PABPN1
mRNA in muscle, kidney and cultured myoblasts plotted as mRNA amount relative to timepoint T = 0 h (n = 3 samples per timepoint). Data are
mean ± SD.
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cultured myoblasts compared to muscle tissue (Figure 4C).
We analyzed the stability of PABPN1 transcripts in cul-
tured myoblasts. As observed in skeletal muscle tissue, the
2.1 kb PABPN1 transcript was the predominant transcript
in myoblasts (data not shown). However, in contrast to
muscle tissue, the 2.1 kb PABPN1 transcript was ex-
tremely stable in myoblasts (Figure 4D,E; Table 1). As
expected, c-Myc mRNA, a known unstable transcript in
myoblasts [27], had a short half-life compared to the
much longer half-life for GAPDH mRNA, a known stable
transcript (Table 1). These results indicate that the high
levels of PABPN1 in cultured myoblasts, and likely inTable 1 Nuclear poly(A) binding protein 1 (PABPN1)
mRNA is unstable in muscle tissue but stable in cultured
myoblasts
Muscle Kidney Myoblast
PABPN1 2.3 h >>6 h >>6 h
PGC1α 1.7 h 2.6 h ND
GAPDH >>6 h >>6 h >>6 h
c-Myc ND ND 0.3 h
GAPDH glyceraldehyde 3-phosphate dehydrogenase, ND not determined,
PGC1α peroxisome proliferator-activated receptor gamma coactivator 1α.myoblasts present during muscle regeneration, is due at
least in part to the increase in PABPN1 mRNA stability in
those cells compared to muscle tissue. Taken together, our
results suggest that PABPN1 expression in different
tissues or during muscle regeneration is regulated by a
post-transcriptional mechanism that modulates tran-
script stability.
Discussion
Studying PABPN1 specifically in skeletal muscle is crit-
ical for defining the mechanisms which make this tissue
uniquely susceptible to the mutation causing OPMD.
Here, we report that steady-state levels of PABPN1
mRNA and protein are low in skeletal muscle and that
expression of PABPN1 in this tissue is controlled, at
least in part, by post-transcriptional regulation of RNA
levels. We also demonstrate that PABPN1 levels are
modulated during muscle repair providing further sup-
port for regulation of PABPN1 expression in this tissue.
PABPN1 is not the only ubiquitous protein with a gen-
eral function in basic cellular processes whose expression
level is variable among tissues [28,29]. For example, the ex-
pression of histone H3A, transcription elongation factor
A1 (TCEA1) and heterogeneous nuclear ribonucleoprotein
Figure 5 Low levels of nuclear poly(A) binding protein 1
(PABPN1) in skeletal muscle may predispose this tissue to the
deleterious effects of alanine-expanded PABPN1. We show
muscle has lower levels of PABPN1 compared to other tissues in
normal individuals (N) but these levels are adequate for normal
tissue function. In patients with oculopharyngeal muscular dystrophy
(OPMD), functional levels of PABPN1 could be decreased in all
tissues due to expression of mutant PABPN1. However, muscle-
specific pathology ensues in autosomal dominant OPMD because
the levels of PABPN1 fall below the threshold required to maintain
proper tissue function.
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whereas levels of GAPDH, β-actin and histone H2A are
among the most variable within tissues [29]. These differ-
ences in expression levels are most likely related to intrin-
sic properties of individual tissues and reflect differences in
metabolic activity and cellular structure.
The extremely low levels of PABPN1 in skeletal
muscle compared to other tissues may indicate a low re-
quirement for this factor in basal muscle metabolism
and maintenance. Skeletal muscle is distinctly character-
ized by multinucleated, post-mitotic cells with a very
specialized function and low complexity transcriptome
[30,31]. In skeletal muscle, a small number of genes con-
tribute to a large fraction of the total mRNA pool, with
the ten most expressed genes in muscle accounting for
20% to 40% of the total mRNA [31]. The most abundant
transcripts in skeletal muscle encode proteins involved
in contraction, glucose metabolism, ATP production and
ribosomal proteins [30,31], consistent with the role of
this tissue in movement and metabolism. Such tran-
scripts encoding proteins involved in general cellular
functions are usually stable with low turnover [27,32].
Therefore, the low complexity of the skeletal muscle
transcriptome associated with low turnover of a signifi-
cant fraction of its transcripts may explain why skeletal
muscle has low requirements for a protein involved in
mRNA metabolism such as PABPN1.
Our data indicate the low levels of PABPN1 in skeletal
muscle are, at least in part, determined at the level of
regulation of PABPN1 transcript stability. Regulation of
mRNA decay rate is a key factor in determining the ex-
pression pattern of many genes allowing rapid adapta-
tion to changing cellular requirements [33,34]. PABPN1
levels increase significantly during skeletal muscle regen-
eration suggesting a greater requirement for PABPN1 in
myoblasts and non-myogenic cells such as inflammatory
cells, which may be due to their highly proliferative sta-
tus and to a more complex transcriptome compared to
uninjured muscle tissue. As the increased levels of PABPN1
in regenerating muscle correlate with an increased tran-
script stability in myoblasts and subsequent increase in the
steady-state levels of PABPN1 transcript, we suggest
that skeletal muscle employs a post-transcriptional
mechanism to control PABPN1 levels according to the
tissue requirements.
mRNA decay rates are modulated by an interplay of
specific stabilizing or destabilizing factors with the tran-
script, such as RNA-binding proteins and/or miRNAs
and their associated enzymes [35]. One of the most
studied post-transcriptional pathways is orchestrated by
a variety of RNA-binding proteins that interact with AU-
rich elements (ARE) within the 3′UTR of mRNAs
[33,36] and many unstable mRNAs expressed in muscle
contain AU-rich elements in their 3′UTRs [27]. As themain 2.1 kb PABPN1 transcript expressed in skeletal
muscle harbors an ARE in the 3′UTR, we speculate this
pathway is a strong candidate for the control of PABPN1
levels in skeletal muscle.
The specific PABPN1 expression pattern observed in
skeletal muscle may be an important feature that makes
this tissue more susceptible than others to the mutations
in PABPN1 that cause the muscle-specific disease OPMD.
Whether the alanine expansion in PABPN1 leads to a
gain-of function or loss-of-function of this protein is un-
known [12,15]. The nuclear aggregates observed in muscle
of OPMD patients may exert toxic effects in the tissue as
hypothesized for other polyglutamine and polyalanine ex-
pansion disorders [37-40]. However, as wild-type PABPN1
can form reversible aggregates in neurons in response to
changes in cell physiology without overt pathology [41],
the toxicity of PABPN1 nuclear aggregates is unlikely to
be the exclusive cause of OPMD etiology. In the loss-of
-function model of OPMD etiology, one mechanism that
could lead to a loss or decrease of PABPN1 function is an
intrinsic reduction in PABPN1 activity caused by the ala-
nine expansion. Although wild-type and mutant PABPN1
appear to have similar polyadenylation activity in vitro [2],
the effects of the alanine expansion on this or other
PABPN1 functions have not yet been addressed in the
context of skeletal muscle in vivo. Another mechanism
that could explain a loss of PABPN1 function is the deple-
tion of the soluble and functional fraction of PABPN1 by
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of OPMD patients. In fact, a recent study that examined
PABPN1 transcript levels in human muscle samples
reported a decrease in steady-state levels of PABPN1
mRNA after the fifth decade of life, the common age for
onset of OPMD symptoms [42]. This study also presented
evidence that this decrease in PABPN1 transcript levels is
accelerated in OPMD patients [42]. These recent findings
support the idea that a loss of PABPN1 function could
contribute to the muscle-specific pathology in OPMD.
Consistent with this idea, overexpression of wild-type
PABPN1 reduces the pathology caused by the expression
of alanine-expanded PABPN1 in both cell and mouse
models of OPMD [43]. In these loss-of-function scenarios,
the low level of PABPN1 in the skeletal muscle may make
this tissue specifically more vulnerable to a further de-
crease in the total amount of functional PABPN1 available
as illustrated in the schematic in Figure 5. The resulting
lowered levels of PABPN1 may then be below the thresh-
old amount of PABPN1 activity that is required for proper
tissue maintenance leading to pathology.Conclusions
Our results demonstrate that PABPN1 steady-state levels
and likely control of expression differ significantly in
skeletal muscle as compared to other tissues, which
could have important implications for understanding the
muscle-specific nature of OPMD. We suggest the low
levels of PABPN1 observed in skeletal muscle may be an
important aspect of this tissue that underlies OPMD
pathology. Further studies are necessary to better com-
prehend the mechanisms and implications of the regula-
tion of PABPN1 expression in skeletal muscle, which
could open avenues for potential therapeutic approaches
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